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eart Failure With Preserved
eft Ventricular Systolic Function
pidemiology, Clinical Characteristics, and Prognosis
aren Hogg, BSC, MBCHB, MRCP,* Karl Swedberg, MD, PHD,†
ohn McMurray, MD, FRCP, FESC, FACC*
lasgow, Scotland; and Go¨teborg, Sweden
Recent cross-sectional, population-based echocardiographic studies show that about half of
all patients with heart failure have preserved left ventricular systolic function (HF-PSF).
Cohort studies of hospitalized patients show a smaller proportion of HF-PSF. Compared to
those with reduced systolic function, patients with HF-PSF are more often female, older, less
likely to have coronary artery disease, and more likely to have hypertension. Patients with
HF-PSF are less symptomatic and receive different pharmacologic therapy than patients with
reduced systolic function. Morbidity and mortality rates in patients with HF-PSF are high
but not quite as high as in patients with reduced systolic function. Though much has recently
been learned about the syndrome of HF-PSF, many questions remain to be answered, not
least how it should be treated. (J Am Coll Cardiol 2004;43:317–27) © 2004 by the
American College of Cardiology Foundationfter years of focus on chronic heart failure (CHF) arising In the Bromley CHF study, all local primary care physi-
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trom reduced left ventricular (LV) systolic function, there
as been a recent growth in interest in the syndrome of
HF associated with “preserved” LV systolic function
1–5). The pathophysiology of this type of heart failure
HF) has been discussed in depth (6–8). The aim of the
resent review is to describe, in detail, the epidemiology,
linical characteristics, and prognosis of patients with HF
nd preserved LV systolic function (PSF).
NCIDENCE OF HF-PSF
here are only two studies of incident cases of CHF
ifferentiating between preserved or reduced systolic func-
ion (9,10). In the Olmsted County study, 216 patients with
ew CHF presenting during the calendar year 1991 were
dentified (5). Of these, 137 (63%) had a recent echocar-
iographic assessment of LV ejection fraction (LVEF), 59
43%) of whom had PSF (LVEF 50%). Five had signif-
cant valve disease—that is, 54 (39%) had PSF and no valve
isease. Patients with PSF were more often female (69% vs.
1%), more likely to have been diagnosed as an out-patient
han an in-patient (86% vs. 71%), and older (78 vs. 74
ears). Coronary heart disease (CHD) (31% vs. 53%),
lectrocardiographic (ECG) evidence of myocardial in-
arction (MI) (15% vs. 42%), radiographic cardiomegaly,
nd pulmonary edema were all less common in patients
ith PSF. Atrial fibrillation (AF) was more frequent (29%
s. 24%), whereas renal dysfunction (serum creatinine 1.3
g/dl) was less common (37% vs. 51%) in patients with PSF.
From the *Department of Cardiology, Western Infirmary, Glasgow, Scotland;
nd †Department of Medicine, Sahlgrenska University Hospital/Ostra, Go¨teborg,
weden.
Manuscript received April 1, 2003; revised manuscript received June 26, 2003,qccepted July 21, 2003.ians were asked to refer new cases of CHF to a special
linic; all local patients admitted to hospital with CHF were
lso identified (10). Of the 332 new cases of CHF detected
etween February 1996 and April 1997, 310 (93%) had an
chocardiogram: 16% of patients were found to have PSF;
8% a “mild to moderate” reduction in LV systolic function;
nd 16% severe LV systolic dysfunction on qualitative
ssessment. The PSF and LV systolic dysfunction groups
ere not compared.
Three factors may explain the discrepancy between these
wo studies. First, the Bromley study included 54 cases
here CHF had developed after acute MI, likely increasing
he proportion with reduced systolic function. Second, the
threshold” for differentiating PSF from “reduced” systolic
ysfunction, which is critical in determining the proportion
ith systolic dysfunction (see following text), may have
iffered between the studies. Third, two biases may have
ccurred. Only 63% of patients in the Olmsted County
tudy had an echocardiogram, compared to 93% in the
romley study. In the Bromley study, 208 of the 332 cases
63%) were identified during hospital admission; these cases
ay be more likely to have reduced LV systolic function.
revalence studies show better agreement than the inci-
ence studies.
REVALENCE OF HF-PSF
ross-sectional population echocardiographic studies.
e identified 10 such studies, 1 confined to Native
mericans (Table 1) (11–20). The number of individuals
creened and their age range varied widely. The means of
dentification of “CHF” also varied, from clinical examina-
ion by a single investigator to the use of an epidemiological
uestionnaire (e.g., Framingham score). The definition of
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Heart Failure With Preserved LV Systolic Function February 4, 2004:317–27SF ranged from qualitative assessment of LVEF to quan-
itative measurement of fractional shortening (FS), a wall
otion score or LVEF; FS was used most frequently but
as certain limitations (see the following text). Table 1 and
igure 1 summarize the findings of the 10 studies.
The prevalence of both types of CHF increased with age.
he proportion of patients with PSF ranged from 40% to
1% (with a mean of 56%) and was probably influenced by
he method used to assess LV systolic function and the
hreshold dividing “preserved” from “reduced.” For example,
S measures systolic function at the base of the heart and
an be normal in patients with apical hypokinesis (whereas
VEF may be reduced). Regarding “threshold,” comparison
f the Copenhagen (13) and Va¨steras (14) studies shows
hat very different proportions of PSF may be calculated
epending upon whether a left ventricular wall motion
ndex (LVWMI) of 1.5 or 1.7 is used as the cut-point
see also FS in the Rotterdam (12) and Helsinki (16) studies
nd EuroHeart Failure survey later) (Table 1). In the
ardiovascular Health Study (CHS), 80% of patients had
n LVEF 0.45, but only 55% had an LVEF 0.55 (18).
here is no simple binary division between “preserved” and
reduced” systolic function. Instead, there is a “border zone”
r “gray area” where there is uncertainty. Some investigators
ay define these patients as having preserved systolic
unction and others as having mildly reduced systolic
unction (Fig. 2).
Only three studies cite separate prevalence figures for
en and women. The proportion of women with HF-PSF
xceeds that of men in all three studies. A case-control study
rom Framingham is consistent with this conclusion (3). In
hat study, 73% of 33 women but only 33% of 40 men with
HF had PSF (also see the EuroHeart Failure survey later).
Though not strictly epidemiological studies, both the
mprovement Programme in Evaluation and Management
f Heart Failure (IMPROVEMENT-HF) (21) study, un-
ertaken in primary care in 15 member countries of the
uropean Society of Cardiology, and the Italian Network
n Congestive Heart Failure (IN-CHF) study (22), con-
ucted in out-patients between 1995 and 1999 in 133 of the
92 Italian cardiology centers, are in close agreement with
Abbreviations and Acronyms
AF  atrial fibrillation
CHF  chronic heart failure
CHD  coronary heart disease
DD  diastolic dysfunction
ECG  electrocardiogram/electrocardiographic
FS  fractional shortening
IVRT  isovolumic relaxation time
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
PSF  preserved systolic functionhe findings summarized earlier. 1ndices of diastolic function. Though often considered
ynomonous with CHF owing to diastolic dysfunction
DD), these two syndromes are not identical. There is the
bvious minority of patients with significant valvular disease
and these have been poorly defined in most of the studies
eviewed). Less obvious may be other causal mechanisms
uch as intermittent myocardial ischemia and AF (23,24). It
s, therefore, of interest to know whether there is evidence of
D in patients with PSF. Four of the population echocar-
iographic studies have also reported indices of DD. In the
HS, mean atrial flow, early flow, and the ratio of early/
trial flow (E/A ratio) did not differ between patients with
F-PSF and those with CHF and reduced systolic function
18). Patients with HF-PSF had increased systolic wall
hickness compared to those with reduced systolic function.
In the Helsinki Ageing Study, there was no difference in
/A ratio, isovolumic relaxation time (IVRT), LV mass, or
V hypertrophy between patients with PSF and those with
educed systolic function, though all of these measures
iffered between patients with CHF and subjects without
16).
In the study from Asturias, all 10 patients with HF-PSF
ad Doppler evidence of DD (11). In eight patients this was
n IVRT110 ms, and in the other two an abnormal mitral
alve E deceleration time (DT) was the cause. Eight of the
0 patients also had echocardiographic LV hypertrophy.
Two extensive studies of DD in the general population
ave recently been reported (20,24). In 2,042 randomly
elected residents of Olmsted County, Minnesota (20), aged
45 years, the prevalence of symptomatic CHF was mea-
ured using the Framingham criteria, and systolic and
iastolic LV function was assessed by Doppler echocardi-
graphy. The prevalence of CHF was 2.2%; 20.8% of the
opulation had mild, 6.6% moderate, and 0.7% severe DD;
% had an LVEF 50%, and 2% an LVEF 40%; CHF
as more frequent in those with systolic or diastolic dys-
unction, although even in subjects with moderate or severe
entricular dysfunction of either type, fewer than half of
hem had CHF (Fig. 3). There was a considerable overlap
etween systolic and DD (e.g., the prevalence of moderate
r severe DD in subjects with an LVEF 50% was 35.2%).
onversely, in subjects with mild, moderate, or severe DD,
0.5%, 19.5%, and 61.5%, respectively, had an LVEF
50%. “Isolated DD” was also common; that is, the
revalence of moderate or severe DD in subjects with an
VEF 50% was 5.9%. Interestingly, DD was as prevalent
n men as in women.
In the second study (24), the prevalence of DD was
easured in 1,274 men and women age 27 to 75 years
mean 51 years) in Augsburg, Germany. The criteria advo-
ated by the European Study Group on Diastolic Heart
ailure were used to measure DD (25). Some 2.3% of the
opulation had an LVEF 45%. Of the remainder, 11.1%
ulfilled the European criteria for DD. The prevalence of
D increased from 2.8% between ages 25 and 35 years, to5.8% in those65 years. The prevalence of DD in healthy
Table 1. Prevalence of Heart Failure With Preserved Left Ventricular Systolic Function: Echocardiographic Cross-Sectional Population Studies
Country (Ref. No.) No. Pts.
Age
Range
(yrs)
Mean
Age
(yrs)
Definition of
Preserved LV
Systolic Function
Prevalence of CHF (%)
How CHF Was Defined
Proportion of Patients
With Preserved LV
Function (%)
Male Female All Male Female All
Spain (Asturias) (11) 391 40 60 LVEF 50% 6.6 3.3 4.9 Framingham criteria — — 59
Netherlands (Rotterdam) (12) 1,698 55–95 65 FS 25% 3.7 4.0 3.9 Physician exam/clinical score — — 71
Denmark (Copenhagen) (13) 2,158 50 — LVWMI 1.5 or
FS 26%
— — 6.4 Boston criteria — — 71
Sweden (Va¨steras) (14) 433 75 75 LVWMI 1.7 or
LVEF 43%
4.0 9.5 6.7 Physician exam — — 46
U.K. (Poole) (15) 817 70–84 76 Qualitative (normal;
mild, moderate,
severe dysfunction)
— — 8.1 Patient self-reported — — 68
Finland (Helsinki)* (16) 501 75–86 — FS 25% 5.2 9.3 8.2 Physician exam/clinical score — — 72
Portugal (EPICA) (17) 5,434 25 68 FS 28%/no LV
regional dyskinesia
and dilation
4.3 4.4 4.4 ESC/Boston criteria 20 55 39
U.S. (CHS) (18,44) a) 4,842 66–103 78 Qualitative† — — 8.8 Panel review 42 67 55
b) 5,888 65 74 Qualitative† – — 5.1‡ Panel review — — 63
U.S. (second SHS) (19) 3,184 47–81 60 LVEF 54% 2.7 3.1 3.0 Hospitalized and Framingham
criteria
26 67 53
U.S. (Olmsted) (20) 2,042 45 63 LVEF 50% 2.7 1.7 2.2 Chart review/Framingham criteria — — 44
*Fifty-one patients with valve disease were excluded. †Normal (LVEF 55%); mild (LVEF 45%–54%), moderate (LVEF 30%–44%) or severe (LVEF 30%) dysfunction. ‡A total of 4.9% when value disease is excluded. a)  data from
reference 18; b)  data from reference 44.
CHF  chronic heart failure; CHS  Cardiovascular Health Study; EPICA  Epidemiologia da Insuficıˆencia Cardiaca e Aprendiazagem; ESC  European Society of Cardiology; FS  fractional shortening; LV  left ventricular;
LVEF  left ventricular ejection fraction; LVWMI  left ventricular wall motion index; SHS  Strong Heart Study.
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Heart Failure With Preserved LV Systolic Function February 4, 2004:317–27ndividuals (i.e., those without cardiac disease, hypertension,
tc.) was 4.3%. Diastolic dysfunction was more common in
en (13.8%) than in women (8.6%, p  0.01), in keeping
ith the Olmsted County Study: 3.1% of subjects had more
evere DD, defined as DD associated with either left atrial
nlargement or diuretic treatment. These new studies tell us
hat Doppler evidence of DD is common in the general
opulation (even more so than systolic dysfunction), is often
symptomatic, and adversely affects prognosis. Paradoxi-
ally, DD is more common in men, despite the predomi-
ance of women with HF-PSF.
ospitalization cohorts. We have identified 12 such stud-
es published since January 2000 (Table 2) (26–37). They
re heterogeneous, ranging from small single-center studies
ith a majority of African American patients, through a
arge sample of Medicare beneficiaries in the United States,
o a countrywide epidemiological survey from France. Most
ave incomplete information on assessment of LV function.
he proportion of patients with PSF was less than in
opulation studies, ranging from 24% to 55% (mean 41%),
onsistent with the evidence that patients with CHF and
igure 1. Prevalence of heart failure in cross-sectional, population-based,
f the bars show the proportion of cases associated with preserved systoliFigure 2. Distribution of left ventricular ejection fracSF have less severe symptoms and are less likely to require
n-patient treatment (see subsequent text).
Patients with PSF were less likely to have had a prior
istory of, or hospitalization for, CHF. As in the population
tudies, there was a clear preponderance of females, and
asoudi et al. (34) confirmed in a multivariate analysis that
emale gender was an independent predictor of PSF in
atients with CHF. The recent Euro Heart Failure survey
f 11,327 hospital discharges from 115 hospitals in 24
uropean countries supports these findings (Fig. 4) (38).
nly 28% of women with CHF had an LVEF of 0.40,
ompared to 51% of men. Patients with PSF were also
lder, though the relationship between age and PSF
ppears to be less strong than that between PSF and
emale gender (34).
YMPTOMS, SIGNS, QUALITY OF LIFE, OTHER
NDICES OF MORBIDITY, AND HOSPITAL STAY
n two studies, the frequency of characteristic symptoms
dyspnea at rest and on exercise; orthopnea) and signs
elevated jugular venous pressure, pedal edema, and pulmo-
ardiographic studies. Black bars show percent prevalence; lower portion
tion. LV  left ventricular.echoction in patients hospitalized with heart failure.
n
s
A
s
r
w
s
g
e
w
A
I
s
P
t
h
s
i
t
h
3
H
Q
t
Q
t
c
r
b
w
n
p
P
P
w
p
t
7
(
(
a
w
e
m
g
C
F
p
m
(
m
r
w
(
a
C
i
i
p
e
T
m
c
p
g
e
i
e
F
M
321JACC Vol. 43, No. 3, 2004 Hogg et al.
February 4, 2004:317–27 Heart Failure With Preserved LV Systolic Functionary crackles) was similar in patients with PSF and reduced
ystolic function (though both these studies enrolled mainly
frican Americans (27,33). The exception was a third heart
ound that was less frequent in PSF. In four studies,
adiographic cardiomegaly was less common in patients
ith PSF. The (IN-CHF) study supports this finding,
howing that patients with PSF have smaller echocardio-
raphic LV dimensions in diastole and systole (22). Philbin
t al. (26) and Varela-Roman et al. (31) found that patients
ith PSF are less likely to be in a higher New York Heart
ssociation (NYHA) class, a finding confirmed in the
N-CHF study (22). Smith et al. (35) recently reported that
evere dyspnea was less common in patents with PSF.
hilbin et al. (26) also measured quality of life (QoL) using
he ladder of life score (maximum score 10  perfect
ealth). The mean score was 6.5 in patients with reduced
ystolic function and 6.4 in those with PSF, scores almost
dentical to those in another study of a clinic cohort, using
he same QoL instrument (39). In a more recent study (6),
owever, both a general QoL instrument (the Short Form
6) and disease-specific one (the Minnesota Living With
eart Failure Questionnaire) showed greater reductions in
oL in patients with reduced LV systolic function than in
hose with PSF (though both groups of patients had a lower
oL than expected for the general population).
Other insights into the morbidity can be gleaned from
he studies summarized in Table 2. The mean Charlson
o-morbidity index was 2.8 and 2.9 in the preserved and
educed systolic function groups, respectively, in the study
y Philbin et al. (26). Smith et al. (35) found that patients
ith reduced systolic function had limitation of a greater
umber of daily living activities.
Ahmed et al. (29) found that 6% of both groups of
atients had been admitted from a nursing home, and
hilbin et al. (26) reported this proportion to be 13% in the
SF group and 10% in the reduced systolic function group.
In the four studies reporting length of hospital stay, there
igure 3. Prevalence of heart failure in subjects in the general population
innesota). CHF  chronic heart failure.as little difference between the two types of CHF. For the mreserved and reduced systolic function groups, respectively,
he durations of stay were 11 versus 11 days (French study),
.5 versus 7.9 days (Philbin et al.), 6.1 versus 7.0 days
Dauterman et al.), and 5.2 versus 5.9 days (Malki et al.)
26–28,30). In a more detailed analysis, both Philbin et al.
nd Malki et al. noted that length of stay tended to increase
ith decreasing LVEF (26,27). Presumably, the powerful
ffect of age offsets this effect when patients are dichoto-
ized into preserved and reduced LV systolic function
roups (the former group being older on average).
ONCOMITANT MEDICAL PROBLEMS
ew of the population-based echocardiographic studies
rovide details on co-morbidity and medical therapy, but
ore is provided by the hospitalization cohort studies
Table 3).
Myocardial infarction (or any evidence of CHD) was
uch less common in patients with PSF than in those with
educed systolic function (though more common in patients
ith HF-PSF than in age- and gender-matched controls)
3). Other evidence of atherosclerotic disease (peripheral
rterial/cerebrovascular) was also less common. The IN-
HF registry reported similar findings (22). In a multivar-
ate analysis, Masoudi et al. (34) found that CHD was an
ndependent predictor of a lower risk of finding PSF in
atients hospitalized with CHF.
Conversely, hypertension (and a suspected hypertensive
tiology) was more common in patients with PSF (40,41).
he IN-CHF study also supports this finding (22). In a
ultivariate analysis, Masoudi et al. (34) were also able to
onfirm that a history of hypertension was an independent
redictor of PSF in patients hospitalized with CHF.
Both of these co-morbidities showed considerable geo-
raphical/ethnic variation. Hypertension was considered the
tiology in about a third of Japanese patients but only 16%
n the predominantly white U.S. patients studied by Philbin
t al. (26). Hypertension appeared to be particularly com-
left ventricular systolic and diastolic dysfunction (Olmsted County Study,withon in Native Americans with PSF (19). Left ventricular
Table 2. Prevalence of Heart Failure With Preserved Left Ventricular Systolic Function: Hospitalization Cohort Studies
First Author/Country
(Ref. No.)
Year
Published No.* Design
Criteria for Preserved LV Systolic
Function
Preserved/Total
(%)
Female %
(P/R)
Mean
Age†
(P/R)
AA %
(P/R)
Philbin (U.S.-MISCHF Registry)
(26)
2000 1,291
(2,906)
MISCHF registry, DRG 127, LV function
assessment within 6 months of
discharge, numeric LVEF available
Echo/RNVG/other LVEF 50% 312/1,291 (24) 70/50 75/74 4/3†
Malki (U.S.-Detroit) (27) 2002 187
(?)
Prospective, clinical, and radiologic
pulmonary congestion; echo within
6 months
Echo LVEF 50% 57/187 (30) 63/46 69/65 60/79
Dauterman (U.S.-California) (28) 2002 782
(1,720)
Retrospective chart review, Medicare
65 yrs, CXR cardiomegaly/pulmonary
edema, LV function measurement,
no C/I to ACE-I
Echo/RNVG/other LVEF 40% or
qualitative LV assessment
238/438 (54) 69/49 — 15/14‡
Ahmed (U.S.-Alabama) (29) 2002 438
(1,091)
Medicare 65 yrs; clinical score;
LV function measurement
LVEF 40% or qualitative
LV assessment
430/782 (55) 69/49 — 14/19
Cohen-Solal (France) (30) 2000 739
(1,058)
Prospective, national epidemiological
survey; Framingham criteria clinical
diagnosis
Echo/RNVG/other LVEF,
echo LVEF 40%
200/438 (46) 51/29 76/71 —
Varela-Roman (Spain) (31) 2002 229
(301)
Prospective, Framingham criteria;
LV function assessment within 2 weeks
Echo LVEF 50% 66/229 (29) 64/33 67/66 —
Tsutsui (Japan) (32) 2001 172
(236)
Retrospective chart review; Framingham
criteria; deaths excluded; echo LVEF
Echo LVEF 50% 61/172 (35) 51/33 69/68 —
Thomas (U.S.-Chicago) (33) 2002 225
(282)
Prospective, consecutive admissions over
4 months; Framingham criteria
Qualitative echo LVEF 45% 104/225 (46) 56/35 59/54 
Masoudi (U.S.-Medicare) (34) 2003 19,710
(33,814)
Medicare (65 yrs) sample April 1998 to
March 1999
LVEF 50% or qualitatively normal
LV systolic function, past history
of CHF or radiographic evidence
6,700/19,710 (35) 79/49 80/78 9/10
Smith (U.S.-Connecticut) (35) 2003 413 Prospective, consecutive admissions,
1996 to 1998; NHANES criteria
Echo/RNVG/other LVEF 40% 200/413 (48) 63/35 73/70 21/25§
Gustafsson (Denmark) (36) 2003 5,491 Randomized controlled trial; admissions
with CHF 1993 to 1996
Echo WMI 1.6 (approximates to
LVEF 48%)
2,218/5,240 (42) 49/33 73/71 —
Varadarajan (U.S.-California) (37) 2003 2,258 Retrospective chart review, 1990 to 1999;
echocardiogram
Echo LVEF 55% 963/2,258 (43) 3/97 70/71 11/10
*Number with LVEF measurement (total number in cohort); it is unclear whether entire cohort had an LVEF measurement. †In years. ‡Nonwhite. §Non-Caucasian. 75% overall.
AA African American; ACE-I angiotensin-converting enzyme inhibitor; CHF chronic heart failure; C/I contraindication; CXR chest X-ray; DRG diagnosis-related group; Echo echocardiographic; ESC European
Society of Cardiology; LV  left ventricular; LVEF  left ventricular ejection fraction; MISCHF Management to Improve Survival in Congestive Heart Failure; P/R  preserved/reduced LV systolic function; RNVG  radionuclide
ventriculogram; WMI  wall motion index.
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February 4, 2004:317–27 Heart Failure With Preserved LV Systolic Functionypertrophy was also more common in patients with PSF
the exception is the study by Thomas et al. [33]).
The incidence of AF was also more frequent in subjects
ith PSF and, overall, was remarkably common in this
atient subset (occurring in a quarter to a third of patients).
n the IN-CHF registry, 16% of low LVEF patients had
F, compared to 25% of patients with an LVEF 45%
22). In a multivariate analysis, Masoudi et al. (34) showed
hat AF was an independent predictor of a higher risk of
SF in patients hospitalized with CHF. This raises the
uestion of whether AF is the primary cause of CHF in
atients with PSF, rather than a secondary problem (23,34).
Diabetes mellitus was also common in both types of
HF. However, apart from the Strong Heart Study (19),
his co-morbidity was not more frequent in patients with
SF, despite prior speculation that diabetes may be a risk
actor for DD (though Redfield et al. [20] found that
iabetes did seem to be associated with an increased
revalence of DD). Moreover, chronic lung disease was
ore common in patients with PSF, raising the concern of
isdiagnosis (42).
There was also no clear difference in the frequency of
enal impairment, creatinine concentration, or creatinine
learance between the two patient groups. This may appear
dd, given the older average age in the PSF cohort.
owever, renal blood flow and renal function may be
epressed more in patients with reduced systolic function,
nd use of angiotensin-converting enzyme (ACE) inhibitors
s greater in these patients.
igure 4. Distribution of left ventricular ejection fraction measured within
en (n  3,249; 57% of total enrolled) enrolled in the EuroHeart Failure
ost recent one was used. Fifty-one percent of men but only 28% of womiEDICAL TREATMENT
se of ACE inhibitors and digoxin was employed less
requently in patients with PSF, as might be expected,
hough the rate of use of both types of medication varied
reatly between studies (Table 3). Beta-blocker use was
reater in the PSF group, although these studies, generally,
redate the recent evidence for this treatment in patients
ith reduced LV systolic function. The findings of the
MPROVEMENT-HF study (21) and the IN-CHF reg-
stry (22) are consistent with the above studies.
Calcium channel blocker use was much greater in patients
ith PSF, reflecting the view that these agents may be of
enefit in this type of CHF (and that they are harmful in
educed systolic function) (43). In the IN-CHF registry, 23%
f patients with an LVEF 45% were taking a calcium
hannel blocker compared to 8% of low-LVEF patients (22).
CONOMIC CONSIDERATIONS
here are few formal cost studies dealing with the problem
f HF-PSF. However, some crude estimate of cost can be
nferred from the rate of hospitalization, which accounts for
ost of the overall cost of CHF to health care systems. This
s primarily driven by length of stay. Approximately 40% of
atients hospitalized with CHF have PSF, and they have
he same length of stay as those with reduced systolic
unction (see previous text). Consequently, 40% of the
verall cost of CHF is probably accounted for by patients
ith PSF (though some expensive procedures are used less
onths of the survey among women (n  2,048; 41% of total enrolled) and
y. Where more than one ejection fraction measurement was available, the
ad a left ventricular ejection fraction 40%.12 m
surven patients with PSF). Support for this conclusion comes
Table 3. Co-Morbidity and Medical Therapy in Chronic Heart Failure: Comparison of Patients With Preserved Left Ventricular Systolic Function to Those With Reduced
Systolic Function
Co-Morbidity
Thomas
P/R (33)
Dauterman
P/R (28)
French
Hospital
P/R (30)
Philbin
P/R (26)
Ahmed
P/R (29)
Malki
P/R (27)
Tsutsui
P/R (32)
Varela-Roman
P/R (31)
Masoudi
P/R (34)
Olmsted
Incidence
P/R (9)
Framingham‡
P/R (3)
CHS
P/R (44)
SHS
P/R (19)
Smith
P/R (35)
Varadarajan
P/R (37)
Gustafsson
P/R (36)
Angina 4/11 — — — — — — — — — 46/36 — — 33/43 — —
Prior MI — 11/15 — — — 26/35 34/36 — 21/38 15/42* 24/69 — 8/39 39/55 — 25/46
Any CHD 22/30 — 31/35 23/35 20/24 — — — 46/65 31/53 57/72 58/78 20/38 24/76 — 25/63
Hypertension 78/74 55/51 54/36 49/43 19/15 88/84 66/44 53/52 69/61 58/50 75/71 59/57 76/8 80/65 27/27 25/23
LVH 22/42* — 31/31* — — — 51/25 49/36* — 17/19* 22/14* — — — — —
AF 19/10* — 42/34 29/24 — — 30/32 45/34* 36/30 29/24* 35/36 15/5* — — 20/26 26/23
PAD — 6/6 — — — 7/13 — — — — — — — — — —
Hyperlipidemia 6/6 — — — — — — 29/35 — — — — — — — —
CVD — 4/6 — — — 5/17 — — 17/18 — — — — 15/15 — —
Smoking 39/45 — — — — 32/46 28/26 24/34 — — 14/14 — 18/13 — — —
Diabetes mellitus 40/34 23/20 — 33/36 25/26 40/50 30/31 17/24 37/40 — 14/22 27/23 70/6 48/48 4/12 13/19
Obesity 62/48 — — — — — — — — — — — — — — —
Renal disease† 15/9 2/3 — — — 26/24 11/14 — 36/47 37/51 — — — 50/52 1/1 60/67
COPD — 33/29 — — 24/24 — — — 34/31 15/14 — — — 31/26 4/9 26/19
Alcohol use 20/37 — — — — — 26/23 — — — — — — — — —
Medications — —
Diuretic 93/95 — 86/97 59/64 30/27 — 61/75 76/79 — 78/78 68/67 59/78 — 79/89 — 78/90
ACE-I 62/85 48/72 63/78 29/48 31/39 — 43/68 12/45 — 31/69 19/36 25/42 — 34/70 — 26/70
Beta-blocker 18/10 — 4/10 23/17 — — 18/26 8/6 — 19/10 32/11 17/7 — 40/34 — —
Digoxin 27/57 — 33/44 30/44 47/51 30/60 39/52 71/56 — 27/55 42/32§ 41/52 — 30/75 — —
CCB 34/14 — 24/12 39/24 — 39/16 51/30 18/12 — 24/15 14/14 31/30 — 50/17 — —
Nitrates — — 41/50 — — — — 30/31 — — 46/39 — — 35/43 — —
*ECG diagnosis. †Variably defined. ‡Comparison of patients with heart failure and not controls. §Patients without atrial fibrillation. Causes of heart failure.
ACE-I  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; CCB  calcium channel blocker; CHD  coronary heart disease; CHS  Cardiovascular Health Study; COPD  chronic obstructive pulmonary disease;
CVD  cerebrovascular disease; MI  myocardial infarction; PAD  peripheral arterial disease; P/R  preserved/reduced left ventricular systolic function; SHS  Strong Heart Study.
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ypes of patient was approximately $8,600 (26).
ROGNOSIS: MORTALITY
opulation-based epidemiological studies. Two of the
opulation-based prevalence studies reported prognosis (the
ramingham case-control study also reports outcomes) (3).
n the Helsinki Ageing Study, four-year mortality in indi-
iduals free of CHF was 30% (16). Of those with CHF, the
ortality rate was 43% among subjects with PSF and 54%
n those with reduced systolic function (46% in patients with
ny CHF). In the Cardiovascular Health Study (CHS), the
.4-year mortality rate in subjects without CHF was 16%
ompared to 45% in those with CHF (44). The mortality
ate in subjects without CHF and with PSF was 25 deaths
er 1,000 patient-years. This rate rose to 87 in subjects with
HF and PSF, 115 in those with CHF and borderline
ystolic function, and 154 per 1,000 patient-years in subjects
ith CHF and reduced systolic function. These figures
ompare to an overall five-year mortality rate of 65% in the
lmsted County incidence study (9). In that investigation,
ge- and gender-adjusted mortality rates were higher than
n individuals free of CHF, though survival was not signif-
cantly different between patients with and without reduced
ystolic function. Patients with CHF in the Framingham
eart Study with reduced LV systolic function had an
nnual mortality rate of 18.9% compared to 4.1% in age-
nd gender-matched controls (over 6.2 years) (3). In pa-
ients with PSF, the annual mortality rate was 8.7% com-
ared to 3% in their matched controls. In an adjusted
nalysis, patients with both types of CHF had four times the
isk of death of their age- and gender-matched controls (3).
he median survival in patients with reduced systolic
unction was 4.3 years, and it was 7.1 years in those with
F-PSF.
Notably in the CHS, the population-attributable mortal-
ty risk was greater for those with HF-PSF (7.5%) than for
HF with reduced systolic function (5.9%). This is ex-
lained by the higher prevalence (combined with moderate
igure 5. Mortality in recent cohort studies of patients hospitalized with
eart failure split according to whether left ventricular ejection fraction
LVEF) is reduced (black triangles) or preserved (black squares).isk) of HF-PSF, compared to the lower prevalence of CHF Cith reduced systolic function (but at higher risk), in the
lderly population studied (44).
Redfield et al. (20) recently described the prognostic
mportance of DD in the population. Mortality increased as
he degree of DD increased, an effect independent of age,
ender, and LVEF. In a multivariate analysis, compared to
ormal diastolic function, mild DD increased the risk of
eath 8.3-fold (p  0.001) and moderate to severe DD
ncreased this risk 10.2-fold (p  0.001).
ospital cohort studies. Nine of the 12 hospital cohort
tudies identified report mortality, with follow-up periods
anging from six months to eight years (the French hospital
urvey also describes in-patient mortality rates) (26–37). It
s not clear whether all these studies calculated mortality in
he same way, that is, whether these include only postdis-
harge deaths or both in-patient (postadmission) and post-
ischarge deaths. Figure 5 shows the mortality rates from
hese studies (and two earlier ones), assuming these were
alculated from admission. Patients with PSF have a better
urvival at all time points from admission. Nevertheless,
atients with PSF still have a high mortality following
dmission to hospital, with rates of 40% to 50% after four to
ve years. The annual death rate in these studies agrees
losely with that in the Framingham Heart Study (3).
ustafsson et al. (36) also showed that survival decreases as
V systolic function decreases in a graded way.
The IN-CHF registry has also reported one-year out-
ome data for out-patients with CHF (22). One-year mor-
ality was 18.8% in patients with an LVEF 35% (Group
), 8.9% in patients with an LVEF 45% (Group 2), and
1.5% in patients with an LVEF between 35% and 45%
Group 3). Though survival was better in these ambulatory
atients compared to hospitalized ones, the differential
ortality effect was still apparent. Notably, an LVEF35%
compared to an LVEF 45%) was an independent predic-
or of survival at one year.
ROGNOSIS: HOSPITAL ADMISSSIONS
opulation-based studies. The risk of hospitalization was
uantified in the Olmsted County incident case study (9).
f patients with reduced LV systolic function, 10% were
ever hospitalized, 41% were hospitalized once, and 49%
ere hospitalized 2 times, for CHF, over five years. These
roportions in patients with PSF were 24%, 51%, and 25%,
espectively. Patients with reduced systolic function had
ignificantly more hospitalizations.
The CHS also reported the risk of nonfatal MI and
troke (44). In subjects with no CHF and PSF these rates
ere 10.9 and 12.5, respectively, per 1,000 patient-years at
isk. The rates increased to 23.3 and 27.5 in patients with
HF and PSF, 37.7 and 50.7 in those with CHF and
orderline systolic function, but fell again to 19.4 and 45.2,
espectively, per 1,000 patient-years, in subjects with CHF
nd reduced systolic function. Even after adjustment in the
ox proportional hazards survival model, the risk of MI and
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unction than in the remainder of individuals with CHF.
his finding is unexplained.
ospital cohort studies. Six of these studies report the risk
f hospital readmission six months to 2.4 years following
ischarge (Table 4) (26,37). Three studies show lower
eadmission rates for CHF in patients with PSF, whereas
wo do not (data not reported in one). In the IN-CHF
egistry, one-year rates of hospitalization for any cause, for
cardiovascular reason, or for worsening CHF were, re-
pectively, 27.1%, 22.6%, and 16.5% in Group 1, 18.4%,
3.2%, and 8.3% in Group 2, and 19.5%, 14.9%, and 9.7%
n Group 3 (22). In a multivariate analysis, however,
educed systolic function (compared to PSF) was not an
ndependent predictor of hospitalization (whereas it was for
eath).
It is important to note that readmission rates in patients
ith PSF are very high—15% to 25% of patients are
eadmitted within six months and a third within a year with
n exacerbation of CHF (and about 45% to 60% at one year
or any reason).
It is clear that both types of CHF have a grim prognosis.
hilbin et al. (26) showed that the six-month rate of death
r readmission was 50% in patients with PSF and 52% in
hose with reduced systolic function.
EMAINING QUESTIONS
any questions remain about the syndrome of HF-PSF.
he proportion of such patients with valve disease has not
een clearly defined in most studies. The higher prevalence
f lung disease seen in patients with reduced systolic
unction raises the possibility of misdiagnosis, especially as
F-PSF is essentially a diagnosis of exclusion (4,42).
eliable non-invasive measures or markers of ventricular
ysfunction are badly needed, but it is not clear whether
atriuretic peptides will fulfill this need (45). Similarly, the
ole of AF requires clarification. Is it AF that is the cause of
HF in many of these patients? Or does AF only precipi-
ate CHF because of underlying DD?
The interaction between this type of CHF and AF is
urther confounded by evidence that DD is itself a predictor
f future AF (23). Also, why is HF-PSF more a problem for
omen than for men? As DD appears to be more common
Table 4. Hospital Re-Admission Rates in Pati
Study (Ref. No.) Follow-Up
Philbin et al. (26) 6 months
Malki et al. (27) 6 months
Ahmed et al. (29) 6 months
Smith et al. (35) 6 months
Dauterman et al. (28) 12 months
Tsutsui et al. (32) 2.4 years (mean)
*It is not entirely clear from the original study whether thes
CHF  chronic heart failure; P/R  preserved/reducedn men it would seem that the female left ventricle is lessble to cope with DD. This is surprising given the more
avorable remodeling changes seen in the overloaded female
V (46). Indeed, the pathophysiology of this type of CHF
emains poorly explained, and it may have as much to do
ith peripheral mechanisms as with cardiac dysfunction
47). The greatest question of all, of course, is how to treat
hese patients. Symptom control is important. However, the
nding from the CHS that the population-attributable risk
or deaths from CHF is greater for PSF than for reduced
ystolic function emphasizes the public health imperative of
eveloping treatments to reduce mortality (and morbidity)
n these patients (48–50).
The CHARM-Preserved trial (using the ARB candesar-
an) showed that candesartan reduced the risk of hospital
dmission for worsening heart failure but did not affect
ortality. Other outcome studies with an ARB, ACE
nhibitor, and beta-blocker are ongoing (48–50). From a
athophysiological basis, it would also be of interest to study
n aldosterone antagonist in this syndrome (6–8). Unfor-
unately, no study to date has provided detailed data on the
auses of death in patients with HF-PSF, information that
hould be of value in the development and testing of
reatments for this type of CHF.
eprint requests and correspondence: Prof. John J. V. McMur-
ay, Department of Cardiology, Western Infirmary, Glasgow, G12
QQ, United Kingdom. E-mail: j.mcmurray@bio.gla.ac.uk.
EFERENCES
1. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and
prognosis of diastolic heart failure: an epidemiologic perspective. J Am
Coll Cardiol 1995;26:1565–74.
2. Dauterman KW, Massie BM, Gheorghiade M. Heart failure associ-
ated with preserved systolic function: a common and costly clinical
entity. Am Heart J 1998;135:S310–9.
3. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in
subjects with normal versus reduced left ventricular ejection fraction:
prevalence and mortality in a population-based cohort. J Am Coll
Cardiol 1999;33:1948–55.
4. Vasan RS, Levy D. Defining diastolic heart failure: a call for stan-
dardized diagnostic criteria. Circulation 2000;101:2118–21.
5. Senni M, Redfield MM. Heart failure with preserved systolic function.
A different natural history? J Am Coll Cardiol 2001;38:1277–82.
6. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological
characterization of isolated diastolic heart failure in comparison to
systolic heart failure. JAMA 2002;288:2144–50.
7. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and
diastolic heart failure. Part II: causal mechanisms and treatment.
With CHF
Re-Admission (%) Any Re-Admission (%)
P/R P/R
23/23 44/42
— 26/33*
14/23 —
16/22 46/46
33/31 58/58
36/48 —
eadmissions for any reason or just for worsening CHF.
ntricular systolic function.ents
CHF
e are r
left veCirculation 2002;105:1503–8.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
327JACC Vol. 43, No. 3, 2004 Hogg et al.
February 4, 2004:317–27 Heart Failure With Preserved LV Systolic Function8. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and
diastolic heart failure. Part I: diagnosis, prognosis, and measurements
of diastolic function. Circulation 2002;105:1387–93.
9. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart
failure in the community: a study of all incident cases in Olmsted
County, Minnesota, in 1991. Circulation 1998;98:2282–9.
0. Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with
heart failure: a population-based study. Eur Heart J 2002;23:877–85.
1. Cortina A, Reguero J, Segovia E, et al. Prevalence of heart failure in
Asturias (a region in the north of Spain). Am J Cardiol 2001;87:
1417–9.
2. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart
failure and left ventricular dysfunction in the general population: the
Rotterdam Study. Eur Heart J 1999;20:447–55.
3. Nielsen OW, Hilden J, Larsen CT, Hansen JF. Cross-sectional study
estimating prevalence of heart failure and left ventricular systolic
dysfunction in community patients at risk. Heart 2001;86:172–8.
4. Hedberg P, Lonnberg I, Jonason T, et al. Left ventricular systolic
dysfunction in 75-year-old men and women; a population-based study.
Eur Heart J 2001;22:676–83.
5. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical
characteristics of left ventricular dysfunction among elderly patients in
general practice setting: cross-sectional survey. Br Med J 1999;318:
368–72.
6. Kupari M, Lindroos M, Iivanainen AM, et al. Congestive heart failure
in old age: prevalence, mechanisms and 4-year prognosis in the
Helsinki Ageing Study. J Intern Med 1997;241:387–94.
7. Ceia F, Fonseca C, Mota T, et al., and the EPICA Investigators.
Prevalence of chronic heart failure in Southwestern Europe: the
EPICA study. Eur J Heart Fail 2002;4:531–9.
8. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart
failure with preserved systolic function in patients  or  65 years of
age. CHS Research Group. Cardiovascular Health Study. Am J
Cardiol 2001;87:413–9.
9. Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure
despite normal left ventricular systolic function in a population-based
sample: the Strong Heart Study. Am J Cardiol 2000;86:1090–6.
0. Redfield MM, Jacobsen SJ, Burnett JC Jr., et al. Burden of systolic and
diastolic ventricular dysfunction in the community: appreciating the
scope of the heart failure epidemic. JAMA 2003;289:194–202.
1. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart
failure in primary care (the IMPROVEMENT of Heart Failure
Programme): an international survey. Lancet 2002;360:1631–9.
2. Tarantini L, Faggiano P, Senni M, et al. Clinical features and
prognosis associated with a preserved left ventricular systolic function
in a large cohort of congestive heart failure outpatients managed by
cardiologists. Data from the Italian Network on Congestive Heart
Failure. Ital Heart J 2002;3:656–64.
3. Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic
dysfunction as a predictor of the first diagnosed nonvalvular atrial
fibrillation in 840 elderly men and women. J Am Coll Cardiol
2002;40:1636–44.
4. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular
diastolic dysfunction in the community. Results from a Doppler
echocardiographic-based survey of a population sample. Eur Heart J
2003;24:320–8.
5. European Study Group on Diastolic Heart Failure. How to diagnose
diastolic heart failure. Eur Heart J 1998;19:990–1003.
6. Philbin EF, Rocco TA Jr., Lindenmuth NW, et al. Systolic versus
diastolic heart failure in community practice: clinical features, out-
comes, and the use of angiotensin-converting enzyme inhibitors. Am J
Med 2000;109:605–13.
7. Malki Q, Sharma ND, Afzal A, et al. Clinical presentation, hospital
length of stay, and readmission rate in patients with heart failure with
preserved and decreased left ventricular systolic function. Clin Cardiol
2002;25:149–52.
8. Dauterman KW, Go AS, Rowell R, et al. Congestive heart failure with
preserved systolic function in a statewide sample of community
hospitals. J Card Fail 2001;7:221–8.
9. Ahmed A, Roseman JM, Duxbury AS, et al. Correlates and outcomes
of preserved left ventricular systolic function among older adults
hospitalized with heart failure. Am Heart J 2002;144:365–72.0. Cohen-Solal A, Desnos M, Delahaye F, et al. A national survey of
heart failure in French hospitals. The Myocardiopathy and Heart
Failure Working Group of the French Society of Cardiology, the
National College of General Hospital Cardiologists and the French
Geriatrics Society. Eur Heart J 2000;21:763–9.
1. Varela-Roman A, Gonzalez-Juanatey JR, Basante P, et al. Clinical
characteristics and prognosis of hospitalised inpatients with heart
failure and preserved or reduced left ventricular ejection fraction. Heart
2002;88:249–54.
2. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of
hospitalized patients with congestive heart failure and preserved versus
depressed systolic function. Am J Cardiol 2001;88:530–3.
3. Thomas JT, Kelly RF, Thomas SJ, et al. Utility of history, physical
examination, electrocardiogram, and chest radiograph for differentiat-
ing normal from decreased systolic function in patients with heart
failure. Am J Med 2002;112:437–45.
4. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart
failure with preserved left ventricular systolic function. J Am Coll
Cardiol 2003;41:217–23.
5. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure
patients with preserved ejection fraction: mortality, readmission, and
functional decline. J Am Coll Cardiol 2003;41:1510–8.
6. Gustafsson F, Torp-Pedersen C, Brendorp B, et al. Long-term
survival in patients hospitalized with congestive heart failure: relation
to preserved and reduced left ventricular systolic function. Eur Heart J
2003;24:863–70.
7. Varadarajan P, Pai RG. Prognosis of congestive heart failure in
patients with normal versus reduced ejection fractions: results from a
cohort of 2,258 hospitalized patients. J Card Fail 2003;9:107–12.
8. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure
Survey programme—a survey on the quality of care among patients
with heart failure in Europe. Eur Heart J 2003;24:442–63.
9. Jaarsma T, Halfens R, Abu-Saad HH, et al. Quality of life in older
patients with systolic and diastolic heart failure. Eur J Heart Fail
1999;1:151–60.
0. Vasan RS, Levy D. The role of hypertension in the pathogenesis of
heart failure. A clinical mechanistic overview. Arch Intern Med
1996;156:1789–96.
1. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute
pulmonary edema associated with hypertension. N Engl J Med
2001;344:17–22.
2. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with
suspected heart failure and preserved left ventricular systolic function
suffer from “diastolic heart failure” or from misdiagnosis? A prospec-
tive descriptive study. Br Med J 2000;321:215–8.
3. Kitzman DW. Therapy for diastolic heart failure: on the road from
myths to multicenter trials. J Card Fail 2001;7:229–31.
4. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of
congestive heart failure in elderly persons: influence of left ventricular
systolic function. The Cardiovascular Health Study. Ann Intern Med
2002;137:631–9.
5. Massie BM. Natriuretic peptide measurements for the diagnosis of
“nonsystolic” heart failure. Good news and bad. J Am Coll Cardiol
2003;41:2018–21.
6. Krumholz HM, Larson M, Levy D. Sex differences in cardiac
adaptation to isolated systolic hypertension. Am J Cardiol 1993;72:
310–3.
7. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal
ejection fraction: is it really a disorder of diastolic function? Circulation
2003;107:656–8.
8. Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people
with chronic heart failure: the PEP-CHF study. The PEP Investiga-
tors. Eur J Heart Fail 1999;1:211–7.
9. McMurray J, Ostergren J, Pfeffer M, et al. Clinical features and
contemporary management of patients with low and preserved ejection
fraction heart failure: baseline characteristics of patients in the Can-
desartan in Heart failure-Assessment of Reduction in Mortality and
Morbidity (CHARM) programme. Eur J Heart Fail 2003;5:261–70.
0. Shibata MC, Flather MD, Bohm M, et al. Study of the Effects of
Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors
with heart failure (SENIORS). Rationale and design. Int J Cardiol
2002;86:77–85.
